Danshenol A has strong aldose reductase (AR) inhibitory activity, has IC50 of 0.10 microM which is comparable to that of epalrestat in clinical use. Danshenol A also has antitumor activity in T-24, QGY, K562, Me180 and BIU87 cell lines, shows inhibited growth of K562 (IC50 = 0.53 μg/mL), T-24 (IC50 = 7.94 μg/mL), QGY (IC50 = 4.65 μg/mL) and Me180 (IC50 = 6.89 μg/mL) cell lines.
Fidarestat is an aldose reductase inhibitor (IC50s: 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10, and V301L AKR1B10, respectively). It has the potential to treat diabetic disease.
8-Lavandulylkaempferol exhibits significant inhibitory effects with IC(50) values of 7.10 and 8.11 microM for butyrylcholinesterase and acetylcholinesterase, respectively. It shows inhibitory activities against aldose reductase, with the the IC50 of 0.79 microM.